Ticker News
$CANF News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
CANF: Warrants exercised for ~$4.0M at $2.50; new warrants for 3.18M ADSs issued
Can‑Fite agreed to immediate cash exercise of up to 1,591,738 outstanding warrants at a reduced $2.50 per ADS (down from $5.00), generating approximately $4.0M gross, with closing expected on or about 2026-09-03. In the transaction the company will issue new unregistered warrants to purchase up to 3,183,476 ADSs at $2.50 (immediately exercisable for up to 24 months); the ADSs issuable on exercise are registered on an effective Form F-3 and H.C. Wainwright is exclusive placement agent. Timing: Warrant exercises are already completed, so dilution is already in effect.
Namodenoson boosts gemcitabine chemo activity in pancreatic cancer (preclinical), backing Phase IIb combo trial
Can‐Fite reported preclinical data showing namodenoson increased cleaved caspase‐3 and enhanced apoptosis when combined with gemcitabine in pancreatic cancer models, suggesting the drug weakens tumor survival pathways and makes chemo more effective. The company says these mechanistic results support its planned randomized Phase IIb testing namodenoson with gemcitabine plus nab‐paclitaxel in advanced pancreatic adenocarcinoma; Phase 2a pancreatic results were accepted for presentation at ESMO 2026.
Can‐Fite submits Phase 2 protocol to test piclidenoson in Lowe syndrome (5‐patient open‐label)
Can‐Fite submitted a Phase 2 study protocol to Bambino Gesù Children’s Hospital and signed a collaboration with Fondazione Telethon to launch the first clinical evaluation of piclidenoson in Lowe syndrome, backed by preclinical data showing restoration of OCRL‐dependent cellular function. The open‐label, single‐center pilot will treat 5 genetically confirmed adult patients with oral piclidenoson twice daily for six months; the primary endpoint is improved renal 99mTc‐DMSA uptake (proximal tubular reabsorption) with urinary biomarkers and Fanconi syndrome parameters as secondary endpoints, and positive results are intended to inform regulatory discussions toward potential registration.
CANF: Australian patent allowance for Namodenoson in liver & pancreatic cancer
Can‐Fite said the Australian Patent Office allowed Patent Application No. 2021290439 covering treatment of advanced metastatic cancer, strengthening intellectual property around its Namodenoson oncology program. Namodenoson is in a pivotal Phase 3 for advanced hepatocellular carcinoma and completed a Phase 2a in pancreatic cancer (with a planned Phase 2b combo with gemcitabine), so the allowance supports commercialization/exclusivity in a key market but does not change clinical status or approvals.
Can‐Fite Phase 2a Namodenoson in pancreatic cancer meets safety endpoint, shows durable survival in a subset
An open‐label Phase 2a study of Namodenoson in 20 advanced pancreatic ductal adenocarcinoma patients met its primary safety endpoint and was well tolerated; in an analysis of eight third‐line patients who survived at least two months, median overall survival exceeded 5 months with 62.5% alive ≥5 months and 37.5% ≥7 months, and one second‐line patient remains alive >18 months. The dataset is small and the survival analysis excluded rapidly progressing patients, but results plus preclinical chemo‐sensitization data support Can‐Fite’s plan to advance Namodenoson into a Phase 2b combination study with chemotherapy.
Can‐Fite wins Japan patent allowance for Namodenoson anti‐obesity use
The Japan Patent Office allowed a divisional patent covering the use of A3 adenosine receptor agonists, including Can‐Fite's Namodenoson, to induce fat loss and treat obesity/metabolic disorders, adding Japan to the company’s existing IP protections. This strengthens Namodenoson's global exclusivity and partnering appeal, but the anti‐obesity case is supported by published/preclinical evidence and Namodenoson has not reported pivotal obesity clinical trial results (it is currently in Phase 3 for HCC and Phase 2b for MASH).
Can‐Fite wins Japanese patent allowance for Namodenoson anti‐obesity use
Can‐Fite said the Japan Patent Office allowed a divisional application covering the use of A3 adenosine receptor agonists — explicitly including Namodenoson — to induce fat loss and treat obesity/metabolic disorders. The allowance extends Namodenoson's IP estate into Japan (on top of US, Canada, Australia, Israel) and is supported by a recent peer‐reviewed paper; Namodenoson is an oral, selective A3AR candidate with an established clinical safety database. This is an intellectual‐property milestone only — no new clinical efficacy or regulatory approvals were reported and the obesity market remains competitive (e.g., GLP‐1 therapies).
Can‐Fite to Pitch Phase‐III Assets (Namodenoson, Piclidenoson) at BIO 2026
Can‐Fite will conduct partnering meetings at the BIO International Convention (June 22–25) to seek licensing and commercialization deals for its late‐stage pipeline, focusing on oncology, liver disease and inflammatory disorders. The company highlights two pivotal Phase III programs — Namodenoson (Phase III for HCC, Phase IIb for MASH, Phase IIa in pancreatic cancer) and Piclidenoson (pivotal Phase III in psoriasis) — a safety database of >1,600 patients, and ~ $20M in upfront/milestone payments from prior regional licensing deals.